On Oct 18, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $525 to $555.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $416 to $549.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $475 to $525.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $518 to $535.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $525 to $555.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The expectation of a significant revenue outperformance for FY25 appears to be a prevailing sentiment. This perspective is reinforced by the company's recent quarterly report, which prompted a revision of the estimated earnings per share for FY25, increasing it approximately by 3%.
Intuitive Surgical registered 'strong' results for Q3, particularly excelling in the two most vital metrics—DV5 placements and procedure growth. Seven months post the U.S. approval of da Vinci 5, Intuitive Surgical is experiencing significant post-launch growth momentum. The early adoption of DV5 is surpassing the initial uptake of the fourth-generation system, indicating a promising potential for accelerated growth as we look towards 2025.
The company's Q3 earnings and revenue exceeded expectations, accompanied by a procedure volume growth of 18% which also surpassed the consensus by 100bps. With a series of regulatory approvals for Dv5, it is anticipated that the growth momentum of Dv5 will be maintained, even as it enters into a wider release in the second half of FY25.
The conviction in the sustained upward potential of Intuitive Surgical strengthens, supporting its premium valuation. It stands out as a top-tier long-term growth prospect following the company's performance that surpassed estimates and showcased accelerated growth across various metrics.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月18日，多家华尔街大行更新了$直觉外科公司 (ISRG.US)$的评级，目标价介于525美元至555美元。
富国集团分析师Larry Biegelsen维持买入评级，并将目标价从416美元上调至549美元。
奥本海默控股分析师Suraj Kalia维持持有评级。
斯迪富分析师Rick Wise维持买入评级，并将目标价从475美元上调至525美元。
BTIG分析师Ryan Zimmerman维持买入评级，并将目标价从518美元上调至535美元。
加皇资本市场分析师Shagun Singh Chadha维持买入评级，并将目标价从525美元上调至555美元。
此外，综合报道，$直觉外科公司 (ISRG.US)$近期主要分析师观点如下：
对于FY25的显著营业收入超越预期的期待似乎是一种普遍的情绪。这一观点得到了公司最近季度报告的支持，促使对FY25预计每股收益的修订，预计增长约3%。
直觉外科公司在第三季度取得了‘强劲’的业绩，特别在两个最关键的指标，即DV5放置量和程序增长方面表现出色。在美国批准达芬奇5七个月后，直觉外科公司正经历着显著的发行后增长动力。早期采用DV5的情况正在超越第四代系统的初期吸收，表明了2025年前景光明的加速增长潜力。
公司第三季度的收入和营业收入超出预期，伴随着18%的程序成交量增长，也超过了共识预期100个基点。随着Dv5一系列监管批准的到来，预计Dv5的增长动力将得到维持，即使它在FY25下半年进入更广泛的发布阶段。
对直觉外科公司持续向上潜力的信心增强，支持其高估值。作为一个长期增长前景显著的优等选择，公司表现超出了预期，并展示了在各种指标上的加速增长。
以下为今日7位分析师对$直觉外科公司 (ISRG.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
